Emergent BioSolutions (EBS) said Tuesday that it has obtained exclusive commercial rights in the US and Canada to Hikma Pharmaceuticals' Kloxxado Nasal Spray, an 8 mg naloxone agent approved for the emergency treatment of known or suspected opioid overdose.
Financial terms were not disclosed.
Under the terms of the six-year agreement, Emergent said Hikma will continue to manufacture Kloxxado Nasal Spray 8 mg, which will become part of Emergent's NARCANDirect online distribution network for direct purchasers, such as emergency medical services.
Emergent's shares were up about 3% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。